Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HiLOG: Ofatumumab, HDMP, and Lenalidomide in R/R CLL/SLL
NCT01497496Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2012
- Primary completion
- Sep 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab, lenalidomide in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Moffitt Cancer Center. Started Jan 2012; status: completed.
02
Drugs
ofatumumablenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01497496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01497496.